Exploring the Relationship between Caffeine Consumption, Caffeine Metabolism, and Sleep Behaviours: A Mendelian Randomisation Study

Caffeine and Sleep

Nilabhra R. Das[1, #], Benjamin Woolf[2, 3, 4], Stephanie Page[2], Rebecca C. Richmond[1, 3, 5, *], Jasmine Khouja[2, 3, *]

1. Population Health Sciences, University of Bristol, Bristol, UK
2. School of Psychological Sciences, University of Bristol, Bristol, UK
3. MRC Integrative Epidemiology Unit at the University of Bristol, Bristol, UK
4. MRC Biostatistics Unit at the University of Cambridge, Cambridge, UK
5. NIHR Oxford Health Biomedical Research Centre, University of Oxford, Oxford, UK

* These authors contributed equally to this work.

Corresponding author: Nilabhra R. Das
n.das@uq.edu.au

Acknowledgements

This research was conducted using the UK Biobank Resource under Application Number 16391 and 81499. Quality Control filtering of the UK Biobank data was conducted by R. Mitchell, G. Hemani, T. Dudding, L. Corbin, S. Harrison, L. Paternoster as described in the published protocol (doi:10.5523/bris.1ovaau5sxunp2cv8rcy88688v). The MRC IEU UK Biobank GWAS pipeline was developed by B. Elsworth, R. Mitchell, C. Raistrick, L. Paternoster, G. Hemani, T. Gaunt (doi:10.5523/bris.1ovaau5sxunp2cv8rcy88688v).

Funding

This work was supported by Cancer Research UK (grant number C18281/A29019). BW works in the Medical Research Council Biostatistics Unit at the University of Cambridge which is supported by the Medical Research Council and the University of Cambridge (grant code MC_UU_00040/1). JK (grant code MC_UU_00011/7) and RCR (grant code MC_UU_00011/1) work in the Medical Research Council Integrative Epidemiology Unit at the University of Bristol which is supported by the Medical Research Council and the University of Bristol. RCR is supported by the National Institute for Health and Care Research (NIHR) Oxford Health Biomedical Research Centre. The views expressed are those of the author(s) and not necessarily those of the NIHR or the Department of Health and Social Care. NIHR Oxford Health Biomedical Research Centre grant reference number: NIHR203316.

Conflicts of interest

The authors declare no conflicts of interest related to this study.

[#]Present address: Translational Research Institute, 37 Kent Street, Woolloongabba, Queensland 4102, Australia

Abstract

Higher consumption of caffeinated beverages is associated with disturbed sleep patterns. Using genetic variants as proxies for caffeine consumption, caffeine metabolism, and sleep traits, we investigated whether this association reflects a direct effect of caffeine. Genetic variants associated with caffeine consumption (n=407,072), caffeine metabolism (n=9,876), chronotype (n=449,734), daytime napping (n=452,633), daytime sleepiness (n=452,071), getting up in morning (n=385,949), insomnia (n=453,379), and sleep duration (n=446,118) identified in individuals from several studies, including the UK Biobank, were used to explore bi-directional causal relationship between caffeine and sleep using a series of univariable Mendelian Randomisation analyses. We used multivariable Mendelian Randomisation to explore the direct effects of caffeine consumption on sleep behaviours while adjusting for metabolism and vice-versa. Higher consumption decreased daytime sleepiness ($\beta_{univariable}$=-0.044, 95%CI [-0.065,-0.023], p<0.001; $\beta_{multivariable}$=-0.034, 95%CI [-0.058,-0.009], p=0.010), while faster caffeine metabolism, indicative of less caffeine exposure per beverage consumed, decreased the likelihood of daytime napping ($\beta_{univariable}$=-0.024, 95%CI [-0.037,-0.011], p<0.001; $\beta_{multivariable}$=-0.021, 95%CI [-0.042,0.000], p=0.051). Being an evening person decreased caffeine consumption ($\beta_{univariable}$=-0.044, 95%CI [-0.078,-0.010], p=0.010). Caffeine consumption/metabolism was not causally related to sleep duration or insomnia. We found no clear evidence for effects of caffeine consumption/metabolism on sleep among non-current caffeine consumers when assessing possible pleiotropy. Overall, sleep appears to be impacted by caffeine in a way that influences daytime alertness rather than night-time sleep characteristics. However, the presence of weak instruments for caffeine metabolism and significant heterogeneity warrants further research with larger and diverse samples to better understand the causal pathway between caffeine and sleep.

Keywords: Mendelian randomization; sleep; genetics; caffeine; metabolites

Introduction

In the National Diet and Nutrition Survey 2008-10
(https://www.gov.uk/government/collections/national-diet-and-nutrition-survey), 95% of
individuals in the UK reported caffeine consumption in the form of tea, coffee, energy
drinks, chocolate, or other snacks and beverages (1), and in a 2013 study (2), 85% of US
residents reported drinking at least one caffeinated beverage per day. Caffeine may
increase alertness and concentration (3), although caffeine consumption has also been
associated with several adverse effects, including caffeine addiction, poorer sleep quality,
and reduced sleep efficiency (4,5). A recent review of 58 independent epidemiological
studies and randomised controlled trials investigated the association of caffeine
consumption with poor sleep including insomnia (5). The review found that adolescents and
adults with high caffeine intake from tea, coffee, and soda were 1.9 times more likely to
have trouble sleeping and 1.8 times more likely to feel sleepy in the morning compared to
those with lower caffeine intake. Previous studies have highlighted strong associations
between poor sleep quality or disturbed sleep and major health issues such as
cardiovascular disease and metabolic disorders, diabetes mellitus, as well as respiratory
disorders (6). Therefore, a deeper understanding of the impact of caffeine consumption on
sleep behaviours could aid public health messaging and facilitate effective dietary advice on
caffeine consumption.

The effects of caffeinated product consumption on sleep have previously been attributed to
the presence of caffeine in the bloodstream (7). Following ingestion, caffeine is almost
completely metabolised (~95%). Less than 3% of caffeine remains unchanged and is excreted
through urine (8). Of the 95% of caffeine (chemical name: 1,3,7-trimethylxanthine [137X])
that is metabolised, 70-80% is metabolised in the liver by the CYP1A2 enzyme to form
paraxanthine (chemical name: 1,7-dimethylxanthine [17X]) (9–11). Caffeine exposure
(presence of caffeine in bloodstream) for an individual depends on how quickly they
metabolise caffeine, which can be quantified using the caffeine metabolite ratio (CMR) - the
ratio of paraxanthine to caffeine (7) (**Supplementary Figure 1**). Those with a higher CMR are
exposed to less caffeine given a fixed level of intake, therefore could be at lower risk of
sleep issues due to caffeine exposure (12,13).

The extent to which caffeine affects sleep behaviours in the general population has not
been fully established. Traditional epidemiological studies which have been used to explore
the influence of caffeine consumption on sleep behaviour may be limited by reverse
causality (i.e., where poor sleep and daytime sleepiness in turn influence caffeine intake (5))
as well as residual confounding (3) by factors including diet, physical activity, other
substances like smoking or alcohol use, and socio-economic position (4). Additionally,
caffeine consumption measured by self-reported cups of tea and/or coffee per day may be
prone to measurement error, especially as individuals are more likely to misremember their
consumption patterns (14). On the other hand, CMR is a more objective measure of caffeine
exposure, calculated by profiling blood plasma levels of caffeine metabolites (7).

Mendelian Randomisation (MR) is a causal method that helps mitigate the limitations of
observational study design by employing genetic variants as instruments (instrumental
variables or IV) for exploring the relationship between exposure and outcome (15).
However, MR results provide valid causal inference only when several MR assumptions are
met (**Figure 1**). The core assumptions are (16):

1. IV1 ("relevance"): instruments must be associated with the exposure,
2. IV2 ("exchangeability" or "independence"): there are no confounders of the
association between instruments and the outcome,
3. IV3 ("exclusion restriction"): instruments are not related to the outcome other than
via the exposure.
126
Genetic variants (single nucleotide polymorphisms or SNPs) identified from genome-wide
association studies (GWASs) are used as instruments (i.e., a proxy for actual exposure) in
MR. Genetic variants are randomly assigned during meiosis and fixed at conception and
cannot be changed as a result of exposure to confounding variables post-conception. Hence,
MR mitigates reverse causation, residual confounding, and tests for causal effects of
exposure on outcome without bias given non-violation of MR assumptions.

A previous study using the MR approach found that higher plasma caffeine affected
chronotype (morning/evening preference) but was not linked with other sleep traits,
concluding that the associations between caffeine and poor sleep might be driven by shared
environmental factors (3). However, using caffeine metabolism (substituting consumption)
in an univariable MR framework to estimate the effects of caffeine on sleep behaviours, as
was done in this previous study, may potentially lead to ambiguous results. Individuals with
faster CMR, i.e., lower levels of caffeine in blood per beverage, consume more caffeinated
products because the effects of caffeine wear off faster.

The investigation of caffeine consumption in an MR framework also remains challenging. A
recent study by Woolf et. al. (17) has revealed that 16 SNPs associated with caffeine
consumption act through caffeine metabolism, while the other half are linked with
behavioural traits like smoking, alcohol consumption, education, and physical activity, which
are likely to violate the IV2 assumption. This potentially renders caffeine consumption SNPs
as invalid instruments. Moreover, evidence from a previous study suggests that individuals
with higher genetically predicted caffeine metabolism rates, tend to consume higher
amounts of caffeine on average to experience caffeine's alertness-promoting effects (18).
This may influence the estimated total effects of CMR because the genetic variants
associated with faster metabolism may also lead to higher caffeine intake. Hence, estimated
total effects of CMR may reflect the biological impact of faster caffeine metabolism
combined with the behavioural impact of higher caffeine consumption.

One alternative is to employ genetic variants for caffeine consumption (cups per day, CPD)
and caffeine metabolism (CMR) as instruments in a multivariable-MR (MVMR) framework.
MVMR is an extension of MR that can be used to establish causal effects of two or more
related exposures, estimating the direct causal effect of each exposure on an outcome,
conditional on the other exposures included in the model (19). Using this approach, we

aimed to explore the direct effects of caffeine consumption on sleep behaviours accounting
for caffeine metabolism, and direct effects of caffeine metabolism on sleep behaviours
accounting for consumption (**Figure 2**).

Methods

Data Sources

Caffeine consumption GWASs

Summary statistics were obtained from separate GWASs performed on estimated caffeine
consumed from tea, coffee, and combined tea and coffee in a day based on 407,072
individuals of European ancestry in UK Biobank (UKB) (14). Each GWAS was adjusted for age,
sex, genotyping array, and the first 30 genetic principal components (PCs) to adjust for
population stratification. The UKB and the methods used for each GWAS are detailed in the
Supplementary Methods.

Plasma caffeine and caffeine metabolites GWAS

Summary statistics were obtained from a meta-analysis of six GWASs performed on caffeine
metabolism (CMR) and blood plasma caffeine (BPC) based on 9,876 individuals of European
ancestry (7). The GWASs were adjusted for smoking status, age, sex, site of the study,
fasting status, and family structure and/or study specific PCs of ancestry. The meta-GWAS is
discussed in the **Supplementary Methods**.

Sleep behaviour GWASs

Summary statistics on sleep behaviours (chronotype (20), daytime napping (21), daytime
sleepiness (22), getting up in the morning (20), sleeplessness/insomnia (23), and sleep
duration (24)) were obtained from GWASs performed on self-reported traits from
approximately 500,000 individuals of European ancestry in UKB available in the Sleep
Disorders Knowledge Portal (SDKP) (sleepdisordergenetics.org). Details on the UKB data
fields, sample sizes, questions and response choices for sleep behaviours are available in the
Supplementary Methods. We used summary statistics from two separate insomnia GWASs
(25,26) which meta-analysed sleep data from UKB and 23andMe data to cross-check
primary results.

Further, summary statistics from GWAS performed using accelerometer-derived sleep traits
from UKB (27) were obtained for "sleep duration", "least active 5 hours" (L5) and "most
active 10 hours" (M10) (chronotype equivalent), "number of nocturnal sleep episodes" and
"sleep efficiency" (aspects of insomnia), and "diurnal inactivity" (consistent with daytime
napping) available in the SDKP.

Additionally, we conducted our own GWAS for sleep behaviours stratified by caffeine
consumption status (current/non-current) using UK Biobank Resource under application
numbers 16391 and 81499. Stratified-GWASs were performed using the MRC IEU UKB
GWAS pipeline (28) adjusting for sex, genotyping chip, relatedness, and population
stratification. Details of the GWAS pipeline are provided in the **Supplementary Methods**.

Statistical analysis

Univariable MR

First, we used a two-sample MR (2SMR) framework with inverse variance weighted (IVW),
MR-Egger, weighted mode, and weighted median models to assess the total causal effects
of caffeine consumption (CPD) and caffeine metabolism (CMR) on sleep behaviours. These
methods are detailed in **Supplementary Methods**. Exposures were clumped at a linkage
disequilibrium (LD) threshold of $r^2<0.001$, with a clumping window of >10,000kb. Genome-
wide (GW) significant ($p<5x10^{-8}$) SNPs were selected and data were harmonised prior to
performing MR to ensure SNP-exposure and SNP-outcome effects corresponded to the
same effect allele [19,29,30]. We performed 2SMR using Steiger-filtering to ensure the
correct direction of causality i.e. to confirm that the SNPs used to instrument CMR/CPD are
more strongly associated with caffeine metabolism/intake than sleep behaviour [15]. We
removed invalid CPD SNPs that were more strongly associated with sleep behaviours than
caffeine intake (chronotype: 4, daytime napping: 2, getting up in the morning: 4, insomnia:
3, sleep duration: 2) prior to performing MR analyses. No CMR SNPs were removed from the
analyses. Further, we performed the reciprocal MR, using genetic instruments associated
with sleep behaviours to evaluate their effects on caffeine consumption and metabolism.

We used an F statistic exceeding the conventional threshold of 10 to indicate good
instrument strength (IV1) [31]. A non-zero intercept in MR-Egger regression was used to
indicate directional pleiotropic effect (violation of IV2) [32]. We used funnel plots to assess
the presence of horizontal pleiotropy by visually inspecting asymmetry. Cochran's Q statistic
[33] exceeding the number of SNPs included in each model and the I^2 statistic [34] was used
to indicate heterogeneity. We performed leave-one-out analyses to assess where the causal
effect was consistent with removal of individual SNPs. Since GWASs were restricted to
individuals of European ancestry while including genetic principal components as covariates,
potential confounding due to population stratification (IV2) was minimised.

Multivariable MR

We assessed the role of CMR in the relationship between tea/coffee consumption and sleep
behaviours using a two-sample MVMR (2S-MVMR) framework. We selected exposure SNPs
using a GW significance threshold of $p<5x10^{-8}$, then clumped (LD $r^2<0.001$, clumping window
>10,000kb) [19] and harmonised the data [19,29] prior to performing analyses using IVW,
and MVMR-Egger models. These methods are detailed in the **Supplementary Methods**.

We used a conditional F statistic (cF) over 10 to indicate good instrument strength [29,31].
We used weak instrument robust methods – Qhet [30], debias IVW [35], Grapple [36],
GMM, and IVW ME [37] – to check consistency and robustness in cases of weak instrument
strength. Weak instrument robust MR methods are detailed in **Supplementary Methods**.
Cochran's Q statistics larger than number of SNPs included in the model indicate horizontal
pleiotropy. We used pleiotropy robust MVMR-Egger to check consistency of results [33].

Sensitivity analyses

Additionally, we performed 2SMR and 2S-MVMR to assess total effects of CPD and CMR, as
well as direct effects of CPD and CMR, on sleep behaviours in non-current drinkers of tea
and coffee. This serves as a negative control to explore violations of IV2 and IV3
assumptions, since we would not expect to observe effects of caffeine consumption and
metabolism among individuals who do not drink tea or coffee. We assumed any evidence of
causal effects of genetically-predicted increased caffeine intake via tea/coffee consumption
among non-current drinkers of tea and coffee would be due to pleiotropy or population
stratification, which may bias our primary results.

Furthermore, we performed 2SMR and 2S-MVMR using accelerometer-derived sleep traits,
multiple GWASs for insomnia, assessing the effects of blood plasma caffeine levels (as well
as CMR), and substituting total caffeine consumption with only tea consumption and only
coffee consumption to check for consistency in our primary results.

The meta-analysis GWAS for plasma caffeine and caffeine metabolism did not include UKB
data. Hence, there was no overlap in participants between the plasma caffeine and caffeine
metabolism GWAS with sleep traits GWASs. However, since the caffeine consumption
GWASs were conducted on UKB data, there was overlap in participants with the sleep
GWASs. To assess the impact of this, we used MRLap to check for consistency when
accounting for sample overlap between exposures and outcomes in two-sample MR (38).

Analyses were performed in R (version 4.3.3) utilising MendelianRandomization (version
0.10.0), mr.divw (version 0.1.0), MRlap (version 0.0.3.3), MVMR (version 0.4), and
TwoSampleMR (version 0.6.4) R packages. Study findings have been reported according to
the Strengthening the Reporting of Observational Studies in Epidemiology using Mendelian
Randomisation (STROBE-MR) guidelines (https://www.strobe-mr.org/) (**Supplementary**
Table 1) (16,39). Lastly, the study protocol was not pre-registered on any centralised
scientific research databases.

Results

Estimated odds ratios (OR_{IVW-MR} and $OR_{IVW-MVMR}$ from IVW MR and IVW MVMR, respectively)
for binary traits and estimated betas (β_{IVW-MR} and $\beta_{IVW-MVMR}$ from IVW MR and IVW MVMR,
respectively) for continuous traits are reported in the main text. Presented βs correspond to
a change of 1 standard deviation (SD) in outcome for 1 SD increase in exposure; ORs also
represent the odds per SD increase in the exposure.

Effect of caffeine on sleep behaviours

Instrument strength

F statistics for CPD (82.04-106.09) and CMR (84.97) and cFs for CPD (10.89-16.58) passed
the conventional threshold of 10, suggesting good instrument strength (**Supplementary**
Tables 2 & 3). However, cFs for CMR (4.71-5.01) indicated weak conditional instrument
strength (**Supplementary Table 3**). Hence, results from weak instrument robust methods
are also presented in the **Supplementary Material (Supplementary Figure 8)**. Cochran's Q
was greater than the number of SNPs across all sleep traits (**Supplementary Table 4**),
suggesting the presence of SNP heterogeneity. Similarly, I^2 indicated that 51-70% of the

variability of MR effect estimates was due to heterogeneity (**Supplementary Table 4**).
Results for pleiotropy-robust methods are also presented in the **Supplementary Material**
(Supplementary Figures 2, 4, & 8).

Effects of CPD on sleep behaviours

In IVW analyses, we found evidence that higher CPD decreased the likelihood of daytime
napping (β_{IVW-MR}=-0.035, 95%CI [-0.059,-0.012], p=0.004), which attenuated upon
accounting for CMR ($\beta_{IVW-MVMR}$=-0.015, 95%CI [-0.046,0.015], p=0.332) (**Figure 3a**). We found
evidence that higher CPD decreased the likelihood of daytime sleepiness (β_{IVW-MR}=-0.044,
95%CI [-0.065,-0.023], p<0.001) which was slightly attenuated upon accounting for CMR
($\beta_{IVW-MVMR}$=-0.034, 95%CI [-0.058,-0.009], p=0.010), however the confidence intervals still
excluded the null (**Figure 3b**). We found evidence that higher CPD decreased ease of getting
up in the morning (β_{IVW-MR}=-0.045, 95%CI [-0.083,-0.007], p=0.021; $\beta_{IVW-MVMR}$=-0.034, 95%CI
[-0.087,0.018], p=0.209) (**Figure 3c**). We found no clear evidence of any total effects of CPD
or any direct effects of CPD on sleep duration (β_{IVW-MR}=0.019, 95%CI [-0.021,0.059], p=0.360;
$\beta_{IVW-MVMR}$=0.035, 95%CI [-0.019,0.089], p=0.208) (**Figures 3d**), chronotype (β_{IVW-MR}=-0.024,
95%CI [-0.086,0.037], p=0.437; $\beta_{IVW-MVMR}$=-0.012, 95%CI [-0.106,0.082], p=0.807) (**Figure 3e**),
or insomnia (OR$_{IVW-MR}$=0.970, 95%CI [0.832,1.132], p=0.701; OR$_{IVW-MVMR}$=1.005, 95%CI
[0.815,1.239], p=0.965) (**Figure 3f**). We observed a pattern of attenuated effect estimates
across sleep behaviours upon adjusting for CMR, with the exception of the effect of CPD on
sleep duration which strengthened when accounting for CMR (β_{IVW-MR}=0.028, β_{IVW-}
$_{MVMR}$=0.040), although the confidence intervals included the null (**Figure 3d**). Effect
estimates were similar using pleiotropy robust and weak instrument robust MVMR methods
across all sleep behaviours presented in the **Supplementary Results (Supplementary Figure**
8). Additionally, we found weak evidence that higher CPD decreased ease of getting up in
the morning in pleiotropy-robust univariable MR methods, contrary to our primary results
(**Supplementary Figure 2**).

Effects of CMR on sleep behaviours

In IVW analyses, we found evidence that faster caffeine metabolism (CMR) decreased the
likelihood of daytime napping (β_{IVW-MR}=-0.024, 95%CI [-0.037,-0.011], p<0.001; $\beta_{IVW-MVMR}$=-
0.021, 95%CI [-0.042, 0.000], p=0.051) (**Figure 3a**). We found evidence that faster CMR
decreased the ease of getting up (β_{IVW-MR}=-0.030, 95%CI [-0.055,-0.005], p=0.021) which
attenuated when accounting for CPD ($\beta_{IVW-MVMR}$=-0.011, 95%CI [-0.044,0.023], p=0.538)
(**Figure 3c**). We found weak evidence that faster CMR decreased the likelihood of being an
evening person, but again this attenuated when accounting for CPD (β_{IVW-MR}=-0.044, 95%CI
[-0.09,0.002], p=0.058; $\beta_{IVW-MVMR}$=-0.023, 95%CI [-0.086,0.04], p=0.481) (**Figure 3e**).
Additionally, we found no clear evidence of any total effects of CMR or any direct effects of
CMR on daytime sleepiness (β_{IVW-MR}=-0.018, 95%CI [-0.05,0.014], p=0.262; $\beta_{IVW-MVMR}$=-0.015,
95%CI [-0.031,0.002], p=0.086) (**Figure 3b**), sleep duration (β_{IVW-MR}=0.005, 95%CI [-
0.014,0.025], p=0.603; $\beta_{IVW-MVMR}$=-0.010, 95%CI [-0.046,0.026], p=0.578) (**Figures 3d**), or
insomnia (OR$_{IVW-MR}$=1.040, 95%CI [0.973,1.11], p=0.248; OR$_{IVW-MVMR}$=1.010, 95%CI
[0.878,1.162], p=0.890) (**Figure 3f**). We observed patterns of attenuation for the effect of
CMR on sleep behaviours after adjusting for CPD.

Total effect estimates as well as direct effect estimates of CMR on other sleep traits were
consistent across pleiotropy robust and weak instrument robust methods detailed in the
Supplementary Results (Supplementary Figure 8). However, in our pleiotropy robust
univariable MR models, we found evidence that a faster CMR (total effect) increased the
likelihood of daytime sleepiness (**Supplementary Figure 4**), with some supporting evidence
from the MVMR models (**Supplementary Figure 8c**).

Effects of sleep behaviours on caffeine consumption and metabolism

We next evaluated the effects of sleep behaviours (exposure) on CPD and CMR (outcome). F
statistics for sleep behaviours were between 40.76 and 52.79 (**Supplementary Table 5**). Q
statistics were greater than number of SNPs across all sleep traits, indicating the presence of
SNP heterogeneity which was further supported by high I^2 statistics (61-80%) when
considering CPD as the outcome (**Supplementary Table 6**). However, I^2 statistics suggested
that no amount of the variation (0%) was due to heterogeneity when considering CMR as
the outcome (**Supplementary Table 6**). Results for pleiotropy-robust methods are also
presented (**Figure 4**).

Using IVW-MR, we found evidence that being an evening person decreased the amount of
CPD (β_{IVW-MR}=-0.044, 95%CI [-0.078,-0.010], p=0.011). We observed consistent direction of
effect estimates with wider confidence intervals in pleiotropy robust methods (**Figure 4a**).
We found no clear evidence for effects of daytime napping (β_{IVW-MR}=0.026, 95%CI [-
0.065,0.117], p=0.571), daytime sleepiness (β_{IVW-MR}=-0.074, 95%CI [-0.153,0.302], p=0.699),
ease of getting up in morning (β_{IVW-MR}=-0.036, 95%CI [-0.159,0.086], p=0.561), insomnia
(β_{IVW-MR}=-0.021, 95%CI [-0.054, 0.012], p=0.219), or sleep duration (β_{IVW-MR}=0.042, 95%CI [-
0.02,0.104], p=0.187) on CPD (**Figure 4a**), or any effects of sleep behaviours on CMR
(chronotype: β_{IVW-MR}=0.048, 95%CI [-0.101,0.197], p=0.528; daytime napping: β_{IVW-MR}=0.001,
95%CI [-0.409,0.412], p=0.995; daytime sleepiness: β_{IVW-MR}=-0.251, 95%CI [-0.565,1.066],
p=0.547; getting up in morning: β_{IVW-MR}=0.074, 95%CI [-0.320,0.468], p=0.713; insomnia:
β_{IVW-MR}=-0.026, 95%CI [-0.137,0.086], p=0.654; sleep duration: β_{IVW-MR}=0.008, 95%CI [-
0.287,0.302], p=0.958) (**Figure 4b**). Effect estimates were consistent across pleiotropy
robust methods (**Figure 4**).

Lastly, we did not observe any violations of assumptions in any of our bi-directional MR
frameworks as detailed **Supplementary Results**. Sensitivity analyses results and bi-
directional MR assumptions are further detailed in **Supplementary Results (Supplementary**
Figures 3, 5, 6, & 7).

Sensitivity analyses

For the most part, primary MR and MVMR results were replicated among tea consumers
(**Supplementary Figure 15a**), coffee consumers (**Supplementary Figure 15b**), and current
caffeine consumers (**Supplementary Figures 13 & 14**), using different insomnia GWASs
(**Supplementary Figures 9g & 9h**), and when CMR was substituted for BPC (**Supplementary**
Figure 10). However, the total effects of CMR (including substitution with BPC) on
chronotype were not consistent across our sensitivity analyses, where we found evidence
for a positive effect (evening preference) in current caffeine consumers (β_{IVW-MR}=0.034,

95%CI [0.010,0.057], p=0.005), and no evidence of any effects when substituted with BPC
(β_{IVW-MR}=0.020, 95%CI [-0.011,0.051], p=0.209) compared to evidence for a weak inverse
effect in our primary analysis (β_{IVW-MR}=-0.044, 95%CI [-0.09,0.002], p=0.058) (**Supplementary**
Figure 14a).

For accelerometer-derived sleep traits, we found evidence of an inverse effect of CPD on
diurnal inactivity, which remained following adjustment for CMR (β_{IVW-MR}=-0.051, 95%CI [-
0.095,-0.007], p=0.023; $\beta_{IVW-MVMR}$=-0.060, 95%CI [-0.111,-0.008], p=0.028) (**Supplementary**
Figure 9a). Further, we found evidence that higher CPD (unadjusted for CMR) increased
sleep efficiency, which slightly attenuated on adjustment for CMR (OR_{IVW-MR}=1.007, 95%CI
[1.001, 1.013], p=0.019, $OR_{IVW-MVMR}$=1.005, 95%CI [0.999, 1.012], p=0.116) (**Supplementary**
Figure 9f). However, we did not find any total or direct effects of CPD on L5 time
(**Supplementary Figure 9b**), M10 time (**Supplementary Figure 9c**), number of nocturnal
sleep episodes (**Supplementary Figure 9d**), and accelerometer-derived sleep duration
(**Supplementary Figure 9e**), or any effect of CMR on the accelerometer-derived sleep traits
(**Supplementary Figures 9a-f**).

As part of the negative control analysis, we found no clear evidence of any total effects of
CPD or CMR, or direct effects of CPD or CMR on the sleep traits among non-current caffeine
consumers (**Supplementary Figures 11 & 12**).

Additionally, our primary results were replicated after adjusting for sample overlap between
CPD and the sleep traits of interest (**Supplementary Figure 16**).

Sensitivity analyses results are further detailed in **Supplementary Results (Supplementary**
Figures 9, 10, & 13-16).

Discussion

In this study, we explored total and direct effects of caffeine consumption measured as cups
per day (CPD) on sleep behaviours, adjusting for caffeine metabolism (CMR). Furthermore,
we explored the total and direct effects of caffeine measured by CMR on sleep behaviours,
adjusting for CPD. In our univariable and multivariable MR analyses, we observed inverse
effects of increased caffeine consumption from tea/coffee on daytime napping, daytime
sleepiness, and getting up in the morning. We also observed inverse effects of increased
caffeine metabolism on chronotype, daytime napping, daytime sleepiness, and getting up in
the morning. Additionally, we observed an inverse effect of evening chronotype on caffeine
consumption. Consistent with previous MR study findings, we found no clear evidence for
effects of caffeine consumption or metabolism on sleep duration or insomnia (3,40). Our
findings suggest that the effects of caffeine might be more pronounced in daytime alertness
phenotypes (chronotype, daytime napping, and daytime sleepiness) over nocturnal sleep
phenotypes (ease of getting up in the morning, insomnia, and sleep duration).

Findings that higher caffeine consumption decreased the likelihood of daytime napping,
daytime sleepiness, and the ease of getting up are consistent with previous observational
studies (41,42). We observed a pattern of attenuation of the effects of caffeine
consumption when accounting for caffeine metabolism, suggesting that observed effects of

consumed caffeine on sleep behaviours are primarily due to increased circulating caffeine.
However, the direct effects of caffeine consumption were often non-zero, indicating
presence of residual effects from additional constituents of caffeinated drinks such as milk,
antioxidants, and sugar, or residual (genetic) confounding by lifestyle/environmental factors
as previously suggested (3,17). Caffeine tolerance may also interact with the effect of
caffeine consumption independently of metabolism (4), contributing to observed residual
effects of CPD. Further, potential horizontal pleiotropy may stem from genetic variations in
adenosine (a sleep-promoting neurotransmitter blocked by caffeine) receptor genes.
However, we did not observe any evidence of horizontal pleiotropy in our analyses. We
found evidence that a faster caffeine metabolism (CMR) decreased the likelihood of daytime
napping, daytime sleepiness, and the ease of getting up (3). Individuals with genetic variants
associated with faster CMR are more efficient at breaking down and eliminating caffeine
(lesser caffeine exposure for a given consumed amount). Faster CMR may lead to more
rapid onset and offset of caffeine's stimulant effects, resulting in acute alertness benefits
without prolonged exposure to caffeine (less interference with adenosine) that could lead to
sleep disturbances – allowing for a smoother transition between periods of wakefulness and
sleep, thus reducing the physiological need for daytime napping (43).

Similar to Treur and colleagues, we found weak evidence that faster CMR (unadjusted for
CPD) decreased the likelihood of being an evening person (3). Contrarily, we also found
evidence that faster CMR (unadjusted for CPD) increased the likelihood of being an evening
person among current consumers. However, these were attenuated to the null in the CPD-
adjusted MVMR models. Moreover, observed effects of CMR in our analyses were in the
same (inverse) direction as the effects of CPD.

Contrary to a previous study that employed a similar framework to explore the stimulating
effects of nicotine on sleep while adjusting for nicotine metabolism rate (NMR) (44), our
findings indicate contrasting effects of CMR on certain sleep traits (chronotype, daytime
napping, daytime sleepiness, ease of getting up in the morning), where the observed CMR
effects appear to be in the same direction (negative) as that of CPD implying that both a
faster CMR and a higher CPD increase alertness. Differences in direction of effects of
stimulant metabolism rates could stem from different half-lives of the stimulants. The
stimulating effects of caffeine (half-life: 5 hours) are likely to last longer and potentially into
the night compared to nicotine which has a shorter half-life (2 hours). Moreover, while NMR
captures the rate of inactivation of nicotine, CMR is measured as the ratio of paraxanthine
to caffeine, where paraxanthine is also an active stimulant. Evidence from functional studies
suggests that paraxanthine (the primary metabolite of caffeine) imparts a similar and
potentially more efficacious stimulating effect to caffeine (45). The effects of paraxanthine
likely contribute to the inverse direction of observed direct effects of CMR in our analyses. A
faster CMR leads to a more rapid metabolism of caffeine into paraxanthine, resulting in
sustained alertness benefits of paraxanthine without exposure to caffeine for an extended
period. Nonetheless, potential physiological effects of paraxanthine are likely to be
relatively brief, as its half-life is about 25% shorter than that of caffeine (46).

Additionally, Treur and colleagues did not observe any effects of sleep behaviours on
caffeine consumption (3). However, we found evidence that identifying as an evening
person decreased CPD.

Strengths and limitations

This study has several notable strengths. We isolated the effects of caffeine consumption
and metabolism on sleep behaviours by using a novel design which includes caffeine
metabolism ratio (CMR) as a proxy measure for caffeine in MVMR analyses, while
accounting for caffeine consumption (CPD). Additionally, the large sample sizes of GWASs
for caffeine consumption and sleep behaviours increase statistical power to detect effects in
our analyses, compared with previous MR studies (3,40).

However, the study also has some limitations. The small sample size of the caffeine
metabolism GWAS relative to caffeine consumption GWAS reduced power to detect direct
effects of CMR on sleep behaviours. Additionally, we observed presence of heterogeneity,
and pleiotropy in some of our analyses, and weak instrument strength for CPD and CMR in
our MVMR analyses. However, this was largely overcome with the use of pleiotropy-, weak
instrument-, and sample overlap-robust methods (31–33,38), where we observed largely
consistent results. Our primary results were also supported by similar effect estimates
observed among tea consumers, coffee consumers, and current caffeine consumers.
Further, we found no evidence of any effects of CPD or CMR on sleep traits among non-
current caffeine consumers. This analysis serves as a negative control, suggesting evidence
against pleiotropy (19,29).

Participants misremembering or incorrectly reporting caffeine consumption and sleep
behavioural patterns may have introduced measurement error in the self-reported caffeine
consumption and sleep traits (47). While we checked consistency of findings using
accelerometer-derived sleep behaviour data, small sample sizes for accelerometer-derived
sleep trait GWASs resulted in low power to detect effects. However, while MR estimates
can be biased by differential measurement error, they are less affected than observational
estimates from standard regression (37).

MR and MVMR analyses were performed using GWAS summary statistics based on cohorts
primarily of European ancestry. Hence, study findings suffer from a lack of generalisability to
populations with non-European ancestry (19). Moreover, CPD GWAS included exposure to
both caffeinated and de-caffeinated tea/coffee, which may have diluted GWAS signals.
Additionally, there was overlap in participants since GWASs for caffeine consumption and
sleep behaviours were conducted using UKB data which may have led to some biased
estimates (48). However, a simulation study has shown that two-sample MR methods used
in a one-sample setting perform similarly to when used in a two-sample setting (49). The
study further concluded that two-sample MR methods, except for MR-Egger, can be safely
used for one-sample MR performed on large biobanks. Further, we used a sample overlap-
robust method (38) to account for the overlap and observed consistent results.

Future studies should utilise larger GWAS on CMR to cross-check our study findings. UKB is a
non-representative study with about 5.5% participant response rate (50). Future

assessment of the effects of caffeine on sleep traits should be conducted on studies other
than UKB to validate our findings. GWASs based on individuals of non-European ancestry
should be used in future studies to improve generalisability of our study findings or
potentially reveal evidence for differences in the effect of caffeine on sleep behaviours
between ancestries. Finally, using GWASs performed on caffeinated coffee consumption
might further strengthen evidence for effects. Although we observed consistent results in
our sensitivity analyses separating out tea and coffee consumption (contrary to our primary
analyses using combined tea and coffee consumption), the inclusion of decaffeinated coffee
in the coffee consumption measurement may have resulted in a slight underestimation of
the observed effects of caffeine.

Implications

Exploring the relationship between sleep and caffeine consumption is important for
informing public health guidelines for caffeine consumption and sleep hygiene, while
knowledge of genetic predisposition to caffeine metabolism could improve personalised
advice regarding how caffeine consumption might affect sleep. Our findings support the role
of caffeine on certain sleep behaviours (specifically daytime napping and daytime
sleepiness), which could have important implications for public health initiatives aimed at
better sleep hygiene, diet, and overall quality of life. However, the limited evidence for a
(long-term) effect of caffeine consumption and metabolism on sleep duration and insomnia,
indicates that the stimulating effects of caffeine are typically acute, and suggests that the
association between habitual caffeine consumption and poor sleep seen observationally
may be attributed to residual confounding by shared environmental factors.

Conclusion

In conclusion, we found evidence for effects of higher caffeine consumption levels on
certain sleep behaviours (decreased daytime napping and daytime sleepiness, and to a
lesser extent, decreased ease of getting up), and evidence of faster caffeine metabolism on
chronotype (morning preference), and decreased daytime napping and ease getting up. In
our MVMR analyses, we found evidence for effects of higher consumption levels on reduced
daytime sleepiness and evidence for effects of faster metabolism on reduced daytime
napping and daytime sleepiness, suggesting that caffeine plays an important role in
determining daytime alertness. A higher caffeine metabolism rate may allow an individual to
experience caffeine's alertness-promoting effects within a shorter period of time. Thus, the
sleep homeostasis is not disrupted for an extended period of time. This, in turn, could
reduce the need for compensatory sleep which is experienced by individuals with slower
caffeine metabolism. Our findings suggest that faster metabolism of caffeine may not result
in reduced stimulating effects when accounting for the amount of caffeine consumed per
day. Since the stimulating effects of caffeine may be sustained by paraxanthine, which is the
primary metabolite of caffeine, further exploration of the impact of the metabolites of
caffeine on sleep traits is warranted. Moreover, we observed some residual effects of
caffeine consumption after adjusting for caffeine metabolism, suggesting effects due to
additional constituents of tea/coffee, or lifestyle/environmental factors on sleep. We found
no clear evidence for effects of caffeine consumption or metabolism ratio on sleep duration

or insomnia. Finally, we observed effects of being an evening/morning person on caffeine
consumption levels suggesting the presence of a sleep-caffeine-sleep behavioural cycle. Our
findings suggest that the observed relationships between genetically predicted caffeine
consumption, caffeine metabolism, and daytime alertness traits can potentially aid in
catering dietary advice to individuals suffering from sleep disorders. However, weak
strength of the caffeine metabolism instruments could have affected the reliability of our
results and biased our results towards the null. Although we employed multiple weak
instrument-robust methods to improve the robustness of our findings, we suggest that
future studies use better-powered GWASs to validate them.

References

1. Fitt E, Pell D, Cole D. Assessing caffeine intake in the United Kingdom diet. Food
Chem. 2013 Oct 1;140(3):421–6.

2. Mitchell DC, Knight CA, Hockenberry J, Teplansky R, Hartman TJ. Beverage caffeine
intakes in the U.S. Food and Chemical Toxicology. 2014 Jan 1;63:136–42.

3. Treur JL, Gibson M, Taylor AE, Rogers PJ, Munafò MR. Investigating genetic
correlations and causal effects between caffeine consumption and sleep behaviours.
J Sleep Res [Internet]. 2018 Oct 1 [cited 2024 Jun 7];27(5):e12695. Available from:
https://onlinelibrary.wiley.com/doi/full/10.1111/jsr.12695

4. Butt MS, Sultan MT. Coffee and its consumption: Benefits and risks. Crit Rev Food
Sci Nutr. 2011 Apr;51(4):363–73.

5. Clark I, Landolt HP. Coffee, caffeine, and sleep: A systematic review of
epidemiological studies and randomized controlled trials. Sleep Med Rev. 2017 Feb
1;31:70–8.

6. Zee PC, Turek FW. Sleep and Health: Everywhere and in Both Directions. Arch Intern
Med [Internet]. 2006 Sep 18 [cited 2024 Nov 30];166(16):1686–8. Available from:
https://jamanetwork.com/journals/jamainternalmedicine/fullarticle/410811

7. Cornelis MC, Kacprowski T, Menni C, Gustafsson S, Pivin E, Adamski J, et al.
Genome-wide association study of caffeine metabolites provides new insights to
caffeine metabolism and dietary caffeine-consumption behavior. Hum Mol Genet
[Internet]. 2016 Dec 15 [cited 2024 Jun 10];25(24):5472–82. Available from:
https://dx.doi.org/10.1093/hmg/ddw334

8. Kot M, Daniel WA. The relative contribution of human cytochrome P450 isoforms to
the four caffeine oxidation pathways: An in vitro comparative study with cDNA-
expressed P450s including CYP2C isoforms. Biochem Pharmacol. 2008 Aug
15;76(4):543–51.

9. Begas E, Kouvaras E, Tsakalof A, Papakosta S, Asprodini EK. In vivo evaluation of
CYP1A2, CYP2A6, NAT-2 and xanthine oxidase activities in a Greek population
sample by the RP-HPLC monitoring of caffeine metabolic ratios. Biomedical
Chromatography [Internet]. 2007 Feb 1 [cited 2024 Jun 10];21(2):190–200. Available
from: https://onlinelibrary.wiley.com/doi/full/10.1002/bmc.736

10. Benowitz NL, Jacob P, Mayan H, Denaro C. Sympathomimetic effects of paraxanthine
and caffeine in humans. Clin Pharmacol Ther [Internet]. 1995 Dec 1 [cited 2024 Jun

10];58(6):684–91. Available from: https://onlinelibrary.wiley.com/doi/full/10.1016/0009-
9236%2895%2990025-X

11. Kot M, Daniel WA. Caffeine as a marker substrate for testing cytochrome P450
activity in human and rat. 2008;

12. Levy M, Zylber-Katz E. Caffeine metabolism and coffee-attributed sleep disturbances.
Clin Pharmacol Ther [Internet]. 1983 Jun 1 [cited 2025 Mar 28];33(6):770–5. Available
from: https://onlinelibrary.wiley.com/doi/full/10.1038/clpt.1983.105

13. Reichert CF, Veitz S, Bühler M, Gruber G, Deuring G, Rehm SS, et al. Wide awake at
bedtime? Effects of caffeine on sleep and circadian timing in male adolescents – A
randomized crossover trial. Biochem Pharmacol. 2021 Sep 1;191:114283.

14. Abdullah Said M, van de Vegte YJ, Verweij N, van der Harst P. Associations of
Observational and Genetically Determined Caffeine Intake With Coronary Artery
Disease and Diabetes Mellitus. Journal of the American Heart Association:
Cardiovascular and Cerebrovascular Disease [Internet]. 2020 Dec 12 [cited 2024 Jun
10];9(24). Available from: /pmc/articles/PMC7955399/

15. Smith GD, Hemani G. Mendelian randomization: genetic anchors for causal inference
in epidemiological studies. Hum Mol Genet [Internet]. 2014 Sep 15 [cited 2024 Jun
10];23(R1):R89–98. Available from: https://dx.doi.org/10.1093/hmg/ddu328

16. Skrivankova VW, Richmond RC, Woolf BAR, Davies NM, Swanson SA, Vanderweele
TJ, et al. Strengthening the reporting of observational studies in epidemiology using
mendelian randomisation (STROBE-MR): explanation and elaboration. The BMJ
[Internet]. 2021 Oct 26 [cited 2025 Mar 28];375:n2233. Available from:
https://pmc.ncbi.nlm.nih.gov/articles/PMC8546498/

17. Woolf B, Cronjé HT, Zagkos L, Larsson SC, Gill D, Burgess S. Comparison of caffeine
consumption behavior with plasma caffeine levels as exposure measures in drug-
target mendelian randomization. Am J Epidemiol [Internet]. 2024 Dec 2 [cited 2025
Mar 28];193(12). Available from: https://pubmed.ncbi.nlm.nih.gov/38904434/

18. Zagkos L, Cronjé HT, Woolf B, de La Harpe R, Burgess S, Mantzoros CS, et al.
Genetic investigation into the broad health implications of caffeine: evidence from
phenome-wide, proteome-wide and metabolome-wide Mendelian randomization. BMC
Med [Internet]. 2024 Dec 1 [cited 2025 Jun 3];22(1):1–10. Available from:
https://bmcmedicine.biomedcentral.com/articles/10.1186/s12916-024-03298-y

19. Sanderson E, Davey Smith G, Windmeijer F, Bowden J. An examination of
multivariable Mendelian randomization in the single-sample and two-sample summary
data settings. Int J Epidemiol [Internet]. 2019 Jun 1 [cited 2024 Jun 14];48(3):713–27.
Available from: https://pubmed.ncbi.nlm.nih.gov/30535378/

20. Jones SE, Lane JM, Wood AR, van Hees VT, Tyrrell J, Beaumont RN, et al. Genome-
wide association analyses of chronotype in 697,828 individuals provides insights into
circadian rhythms. Nature Communications 2019 10:1 [Internet]. 2019 Jan 29 [cited
2024 Jun 14];10(1):1–11. Available from: https://www.nature.com/articles/s41467-
018-08259-7

21. Dashti HS, Daghlas I, Lane JM, Huang Y, Udler MS, Wang H, et al. Genetic
determinants of daytime napping and effects on cardiometabolic health. Nat Commun

[Internet]. 2021 Dec 1 [cited 2024 Jun 10];12(1). Available from:
https://pubmed.ncbi.nlm.nih.gov/33568662/

22. Wang H, Lane JM, Jones SE, Dashti HS, Ollila HM, Wood AR, et al. Genome-wide
association analysis of self-reported daytime sleepiness identifies 42 loci that suggest
biological subtypes. Nat Commun [Internet]. 2019 Dec 1 [cited 2024 Jun 10];10(1).
Available from: https://pubmed.ncbi.nlm.nih.gov/31409809/

23. Lane JM, Jones SE, Dashti HS, Wood AR, Aragam KG, van Hees VT, et al. Biological
and clinical insights from genetics of insomnia symptoms. Nat Genet [Internet]. 2019
Mar 1 [cited 2024 Aug 18];51(3):387–93. Available from:
https://pubmed.ncbi.nlm.nih.gov/30804566/

24. Dashti HS, Jones SE, Wood AR, Lane JM, van Hees VT, Wang H, et al. Genome-
wide association study identifies genetic loci for self-reported habitual sleep duration
supported by accelerometer-derived estimates. Nat Commun [Internet]. 2019 Dec 1
[cited 2024 Jun 10];10(1). Available from: https://pubmed.ncbi.nlm.nih.gov/30846698/

25. Jansen PR, Watanabe K, Stringer S, Skene N, Bryois J, Hammerschlag AR, et al.
Genome-wide analysis of insomnia in 1,331,010 individuals identifies new risk loci
and functional pathways. Nat Genet [Internet]. 2019 Mar 1 [cited 2024 Aug
18];51(3):394–403. Available from: https://pubmed.ncbi.nlm.nih.gov/30804565/

26. Watanabe K, Jansen PR, Savage JE, Nandakumar P, Wang X, Agee M, et al.
Genome-wide meta-analysis of insomnia prioritizes genes associated with metabolic
and psychiatric pathways. Nature Genetics 2022 54:8 [Internet]. 2022 Jul 14 [cited
2024 Jun 14];54(8):1125–32. Available from: https://www.nature.com/articles/s41588-
022-01124-w

27. Jones SE, van Hees VT, Mazzotti DR, Marques-Vidal P, Sabia S, van der Spek A, et
al. Genetic studies of accelerometer-based sleep measures yield new insights into
human sleep behaviour. Nat Commun [Internet]. 2019 Dec 1 [cited 2024 Aug
26];10(1). Available from: /pmc/articles/PMC6451011/

28. MRC IEU UK Biobank GWAS pipeline version 2 - Datasets - data.bris [Internet]. [cited
2024 Sep 2]. Available from:
https://data.bris.ac.uk/data/dataset/pnoat8cxo0u52p6ynfaekeigi

29. Sanderson E. Multivariable Mendelian Randomization and Mediation. Cold Spring
Harb Perspect Med [Internet]. 2021 Feb 1 [cited 2024 Jun 9];11(2):1–12. Available
from: /pmc/articles/PMC7849347/

30. Sanderson E, Spiller W, Bowden J. Testing and correcting for weak and pleiotropic
instruments in two-sample multivariable Mendelian randomization. Stat Med [Internet].
2021 Nov 10 [cited 2024 Aug 22];40(25):5434–52. Available from:
https://onlinelibrary.wiley.com/doi/full/10.1002/sim.9133

31. Burgess S, Thompson SG. Avoiding bias from weak instruments in Mendelian
randomization studies. Int J Epidemiol [Internet]. 2011 Jun [cited 2024 Jun
10];40(3):755–64. Available from: https://pubmed.ncbi.nlm.nih.gov/21414999/

32. Burgess S, Thompson SG. Interpreting findings from Mendelian randomization using
the MR-Egger method. Eur J Epidemiol [Internet]. 2017 May 1 [cited 2024 Jun
10];32(5):377–89. Available from: https://pubmed.ncbi.nlm.nih.gov/28527048/

33.   Burgess S, Bowden J, Fall T, Ingelsson E, Thompson SG. Sensitivity Analyses for
651   Robust Causal Inference from Mendelian Randomization Analyses with Multiple
652   Genetic Variants. Epidemiology [Internet]. 2017 Jan 1 [cited 2024 Jun 10];28(1):30–
653   42. Available from: https://pubmed.ncbi.nlm.nih.gov/27749700/

654   34.   Higgins JPT, Thompson SG, Deeks JJ, Altman DG. Measuring inconsistency in meta-
655   analyses. BMJ [Internet]. 2003 Sep 6 [cited 2025 Mar 28];327(7414):557–60.
656   Available from: https://pubmed.ncbi.nlm.nih.gov/12958120/

657   35.   Wu Y, Kang H, Ye T. Debiased Multivariable Mendelian Randomization. 2024 Feb 1
658   [cited 2024 Aug 22]; Available from: https://arxiv.org/abs/2402.00307v2

659   36.   Wang J, Zhao Q, Bowden J, Hemani G, Smith GD, Small DS, et al. Causal Inference
660   for Heritable Phenotypic Risk Factors Using Heterogeneous Genetic Instruments.
661   bioRxiv [Internet]. 2020 May 8 [cited 2024 Aug 22];2020.05.06.077982. Available
662   from: https://www.biorxiv.org/content/10.1101/2020.05.06.077982v1

663   37.   Woolf B, Yarmolinsky J, Karhunen V, Tilling K, Gill D. Re-evaluating the robustness of
664   Mendelian randomisation to measurement error. medRxiv [Internet]. 2022 Oct 4 [cited
665   2024 Aug 22];2022.10.02.22280617. Available from:
666   https://www.medrxiv.org/content/10.1101/2022.10.02.22280617v1

667   38.   Mounier N, Kutalik Z. Bias correction for inverse variance weighting Mendelian
668   randomization. Genet Epidemiol [Internet]. 2023 Jun 1 [cited 2025 Mar 6];47(4):314–
669   31. Available from: https://onlinelibrary.wiley.com/doi/full/10.1002/gepi.22522

670   39.   Skrivankova VW, Richmond RC, Woolf BAR, Yarmolinsky J, Davies NM, Swanson
671   SA, et al. Strengthening the Reporting of Observational Studies in Epidemiology
672   Using Mendelian Randomization: The STROBE-MR Statement. JAMA [Internet]. 2021
673   Oct 26 [cited 2025 Mar 28];326(16):1614–21. Available from:
674   https://jamanetwork.com/journals/jama/fullarticle/2785494

675   40.   Cheng H, Wang SM, Liu PW, Huang WC, Yuan J, Zhong DY, et al. Lack of a causal
676   relationship between tea intake and sleep disorders: a two-sample Mendelian
677   randomization study Corresponding to. ARTICLE Medical Data Mining [Internet]. 2024
678   [cited 2024 Sep 4];7(3):17. Available from: https://www.tmrjournals.com/mdm

679   41.   Roehrs T, Roth T. Caffeine: Sleep and daytime sleepiness. Sleep Med Rev. 2008 Apr
680   1;12(2):153–62.

681   42.   Orbeta RL, Overpeck MD, Ramcharran D, Kogan MD, Ledsky R. High caffeine intake
682   in adolescents: associations with difficulty sleeping and feeling tired in the morning.
683   Journal of Adolescent Health. 2006 Apr 1;38(4):451–3.

684   43.   O'callaghan F, Muurlink O, Reid N. Effects of caffeine on sleep quality and daytime
685   functioning. Risk Manag Healthc Policy [Internet]. 2018 [cited 2024 Aug 22];11:263.
686   Available from: /pmc/articles/PMC6292246/

687   44.   Page S, Gibson M, Munafò MR, Khouja J, Richmond RC. Exploring the role of
688   nicotine and smoking in sleep behaviours: A multivariable Mendelian Randomisation
689   study. medRxiv [Internet]. 2024 Aug 2 [cited 2025 Jun 12];2024.08.01.24311349.
690   Available from: https://www.medrxiv.org/content/10.1101/2024.08.01.24311349v1

691   45.   Okuro M, Fujiki N, Kotorii N, Ishimaru Y, Sokoloff P, Nishino S. Effects of
692   Paraxanthine and Caffeine on Sleep, Locomotor Activity, and Body Temperature in

Orexin/Ataxin-3 Transgenic Narcoleptic Mice. Sleep [Internet]. 2010 Jul 1 [cited 2025
Jun 12];33(7):930. Available from: https://pmc.ncbi.nlm.nih.gov/articles/PMC2894435/

46. Lelo A, Birkett D, Robson R, Miners J. Comparative pharmacokinetics of caffeine and
its primary demethylated metabolites paraxanthine, theobromine and theophylline in
man. Br J Clin Pharmacol [Internet]. 1986 Aug 1 [cited 2025 Jun 12];22(2):177–82.
Available from: /doi/pdf/10.1111/j.1365-2125.1986.tb05246.x

47. Marques DR, Pires L, Broomfield NM, Espie CA. Sleep effort and its measurement: A
scoping review. J Sleep Res [Internet]. 2024 [cited 2024 Aug 22];e14206. Available
from: https://onlinelibrary.wiley.com/doi/full/10.1111/jsr.14206

48. Hartwig FP, Davies NM, Hemani G, Smith GD. Two-sample Mendelian randomization:
avoiding the downsides of a powerful, widely applicable but potentially fallible
technique. Int J Epidemiol [Internet]. 2016 Dec 1 [cited 2024 Jun 10];45(6):1717–26.
Available from: https://pubmed.ncbi.nlm.nih.gov/28338968/

49. Minelli C, Del Greco FM, Van Der Plaat DA, Bowden J, Sheehan NA, Thompson J.
The use of two-sample methods for Mendelian randomization analyses on single
large datasets. Int J Epidemiol [Internet]. 2021 Nov 10 [cited 2025 Mar 6];50(5):1651–
9. Available from: https://dx.doi.org/10.1093/ije/dyab084

50. Stamatakis E, Owen KB, Shepherd L, Drayton B, Hamer M, Bauman AE. Is Cohort
Representativeness Passé? Poststratified Associations of Lifestyle Risk Factors with
Mortality in the UK Biobank. Epidemiology [Internet]. 2021 Mar 1 [cited 2025 Mar
6];32(2):179. Available from: https://pmc.ncbi.nlm.nih.gov/articles/PMC7850587/

Figure Legends

Figure 1. Assumption in Mendelian Randomisation (MR) framework. "G" represents the genetic variants, "X" represents the exposure, "Y" represents the outcome, and "U" represents the confounders confounding the relationship between exposure and outcome. "[1]" represents the first assumption (IV1) of the MR framework or "relevance" assumption, "[2]" represents the second assumption (IV2) or "exchangeability" assumption, and "[3]" represents the third assumption (IV3) or "exclusion restriction" assumption.

Figure 2. Multivariable Mendelian Randomisation (MVMR) framework. "G1", "G2", and "G3" represent the genetic variants. "U" represents the confounders confounding the relationship between exposures (caffeine consumption and caffeine metabolism ratio) and outcomes (sleep behaviours). "[1]" represents the first assumption (IV1) of the MVMR framework or "relevance" assumption, "[2]" represents the second assumption (IV2) or "exchangeability" assumption, and "[3]" represents the third assumption (IV3) or "exclusion restriction" assumption.

Figure 3a. MR results of effects of caffeine consumption and caffeine metabolism ratio on daytime napping. Red squares represent the estimated effect sizes (betas or odds ratios (ORs)) for each individual estimation method. The red horizontal lines represent the 95% confidence intervals (95% CI) for the estimated effects. The black vertical line represents the point of no effect. "nSNP" gives the number of single nucleotide polymorphisms (SNPs) used in each estimation method. "IVW MR" gives the total effects estimated using inverse

variance weighted (IVW) Mendelian Randomisation (MR). "IVW MVMR" gives the direct
effects estimated using Multivariable Mendelian Randomisation (MVMR).

Figure 3b. MR results of effects of caffeine consumption and caffeine metabolism ratio on
daytime sleepiness. Red squares represent the estimated effect sizes (betas or odds ratios
(ORs)) for each individual estimation method. The red horizontal lines represent the 95%
confidence intervals (95% CI) for the estimated effects. The black vertical line represents the
point of no effect. "nSNP" gives the number of single nucleotide polymorphisms (SNPs) used
in each estimation method. "IVW MR" gives the total effects estimated using inverse
variance weighted (IVW) Mendelian Randomisation (MR). "IVW MVMR" gives the direct
effects estimated using Multivariable Mendelian Randomisation (MVMR).

Figure 3c. MR results of effects of caffeine consumption and caffeine metabolism ratio on
sleep duration. Red squares represent the estimated effect sizes (betas or odds ratios (ORs))
for each individual estimation method. The red horizontal lines represent the 95%
confidence intervals (95% CI) for the estimated effects. The black vertical line represents the
point of no effect. "nSNP" gives the number of single nucleotide polymorphisms (SNPs) used
in each estimation method. "IVW MR" gives the total effects estimated using inverse
variance weighted (IVW) Mendelian Randomisation (MR). "IVW MVMR" gives the direct
effects estimated using Multivariable Mendelian Randomisation (MVMR).

Figure 3d. MR results of effects of caffeine consumption and caffeine metabolism ratio on
getting up in morning. Red squares represent the estimated effect sizes (betas or odds ratios
(ORs)) for each individual estimation method. The red horizontal lines represent the 95%
confidence intervals (95% CI) for the estimated effects. The black vertical line represents the
point of no effect. "nSNP" gives the number of single nucleotide polymorphisms (SNPs) used
in each estimation method. "IVW MR" gives the total effects estimated using inverse
variance weighted (IVW) Mendelian Randomisation (MR). "IVW MVMR" gives the direct
effects estimated using Multivariable Mendelian Randomisation (MVMR).

Figure 3e. MR results of effects of caffeine consumption and caffeine metabolism ratio on
chronotype. Red squares represent the estimated effect sizes (betas or odds ratios (ORs))
for each individual estimation method. The red horizontal lines represent the 95%
confidence intervals (95% CI) for the estimated effects. The black vertical line represents the
point of no effect. "nSNP" gives the number of single nucleotide polymorphisms (SNPs) used
in each estimation method. "IVW MR" gives the total effects estimated using inverse
variance weighted (IVW) Mendelian Randomisation (MR). "IVW MVMR" gives the direct
effects estimated using Multivariable Mendelian Randomisation (MVMR).

Figure 3f. MR results of effects of caffeine consumption and caffeine metabolism ratio on
insomnia. Red squares represent the estimated effect sizes (betas or odds ratios (ORs)) for
each individual estimation method. The red horizontal lines represent the 95% confidence
intervals (95% CI) for the estimated effects. The black vertical line represents the point of no
effect. "nSNP" gives the number of single nucleotide polymorphisms (SNPs) used in each
estimation method. "IVW MR" gives the total effects estimated using inverse variance

weighted (IVW) Mendelian Randomisation (MR). "IVW MVMR" gives the direct effects
estimated using Multivariable Mendelian Randomisation (MVMR).

Figure 4a. MR results of total effect of sleep behaviours on caffeine consumption. Red
squares represent the estimated effect sizes (betas) for each individual estimation method.
The red horizontal lines represent the 95% confidence intervals (95% CI) for the estimated
effects. The black vertical line represents the point of no effect. "nSNP" gives the number of
single nucleotide polymorphisms (SNP) used in each estimation method.

Figure 4b. MR results of total effect of sleep behaviours on caffeine metabolism ratio. Red
squares represent the estimated effect sizes (betas) for each individual estimation method.
The red horizontal lines represent the 95% confidence intervals (95% CI) for the estimated
effects. The black vertical line represents the point of no effect. "nSNP" gives the number of
single nucleotide polymorphisms (SNP) used in each estimation method.

Method	nSNP			OR	95% CI	p-value
Caffeine consumption						
IVW MR	41			0.970	[0.832, 1.132]	0.701
IVW MVMR	43			1.005	[0.815, 1.239]	0.965
Caffeine metabolism ratio						
IVW MR	3			1.040	[0.973, 1.11]	0.248
IVW MVMR	43			1.010	[0.878, 1.162]	0.890

Insomnia

Caffeine consumption

Chronotype	nSNP		Beta	95% CI	p-value
Inverse variance weighted	148		-0.044	[-0.078, -0.01]	0.011
MR Egger	148		-0.079	[-0.188, 0.031]	0.160
Weighted median	148		-0.047	[-0.08, -0.014]	0.006
Weighted mode	148		-0.049	[-0.119, 0.02]	0.166

Daytime napping	nSNP		Beta	95% CI	p-value
Inverse variance weighted	104		0.026	[-0.065, 0.117]	0.571
MR Egger	104		-0.154	[-0.472, 0.163]	0.343
Weighted median	104		-0.024	[-0.119, 0.071]	0.615
Weighted mode	104		-0.052	[-0.187, 0.084]	0.458

Daytime sleepiness	nSNP		Beta	95% CI	p-value
Inverse variance weighted	36		0.074	[-0.153, 0.302]	0.522
MR Egger	36		-0.198	[-1.192, 0.797]	0.699
Weighted median	36		0.028	[-0.149, 0.205]	0.760
Weighted mode	36		-0.089	[-0.338, 0.159]	0.486

Getting up in morning	nSNP		Beta	95% CI	p-value
Inverse variance weighted	52		-0.036	[-0.159, 0.086]	0.561
MR Egger	52		-0.396	[-0.793, 0.001]	0.056
Weighted median	52		-0.032	[-0.128, 0.064]	0.513
Weighted mode	52		-0.051	[-0.211, 0.108]	0.529

Insomnia	nSNP		Beta	95% CI	p-value
Inverse variance weighted	38		-0.021	[-0.054, 0.012]	0.219
MR Egger	38		-0.013	[-0.127, 0.101]	0.822
Weighted median	38		-0.029	[-0.055, -0.003]	0.030
Weighted mode	38		-0.038	[-0.078, 0.002]	0.074

Sleep duration	nSNP		Beta	95% CI	p-value
Inverse variance weighted	66		0.042	[-0.02, 0.104]	0.187
MR Egger	66		0.110	[-0.128, 0.348]	0.367
Weighted median	66		0.005	[-0.06, 0.069]	0.890
Weighted mode	66		-0.076	[-0.229, 0.077]	0.334

Caffeine metabolism ratio

Method	nSNP	Beta	95% CI	p-value
Caffeine consumption				
IVW MR	44	-0.044	[-0.065, -0.023]	<0.001
IVW MVMR	43	-0.034	[-0.058, -0.009]	0.01
Caffeine metabolism ratio				
IVW MR	3	-0.018	[-0.05, 0.014]	0.262
IVW MVMR	43	-0.015	[-0.031, 0.002]	0.086

Daytime sleepiness

Method	nSNP		Beta	95% CI	p-value
Caffeine consumption					
IVW MR	37		-0.045	[-0.083, -0.007]	0.021
IVW MVMR	40		-0.034	[-0.087, 0.018]	0.209
Caffeine metabolism ratio					
IVW MR	3		-0.030	[-0.055, -0.005]	0.021
IVW MVMR	40		-0.011	[-0.044, 0.023]	0.538

Getting up in morning

Method	nSNP		Beta	95% CI	p-value
Caffeine consumption					
IVW MR	39		-0.024	[-0.086, 0.037]	0.437
IVW MVMR	43		-0.012	[-0.106, 0.082]	0.807
Caffeine metabolism ratio					
IVW MR	3		-0.044	[-0.09, 0.002]	0.058
IVW MVMR	43		-0.023	[-0.086, 0.04]	0.481

Chronotype